title: p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
abstract: Cancerous inhibitor of PP2A (p90/CIP2A) was recently characterized as an innovative oncoprotein in human malignancies. p90/CIP2A inhibited c-Myc-associated PP2A phosphatase activity to promote cell proliferation and tumor growth. A growing number of studies have demonstrated that the overexpression of p90/CIP2A in various human malignancies. But the function of p90/CIP2A in cancer progression is still poorly understood. In the current research, we aim to explore the biological function of p90/CIP2A in breast cancer. shRNA knockdown was performed in MDA-MB-231 and LM2-4 cell lines. Cell proliferation assay, colony formation assay and flow cytometry were carried out to evaluate the role of p90/CIP2A in cell proliferation and apoptosis. p90/CIP2A depletion in breast cancer cells inhibited proliferation and increased paclitaxel-induced apoptosis. Furthermore, p90/CIP2A silencing down-regulated the expression of c-Myc and the level of p-ERK1/2. Taken together, our data suggest that p90/CIP2A as a crucial oncoprotein has been involved in cell proliferation and apoptosis, which may serve as a therapeutic target in breast cancer treatment.
authors.affiliation: Department of Biology Sciences, The University of Texas at El Paso, El Paso, TX, 79968, USA.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Liu
authors.forename: Bo
authors.initials: B
authors.lastname: Peng
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.forename: Ningjing
authors.initials: N
authors.lastname: Lei
authors.forename: Wenjie
authors.initials: W
authors.lastname: Li
authors.forename: Jian-Ying
authors.initials: JY
authors.lastname: Zhang
mesh_terms: D017209:Apoptosis / Q000235:genetics / Q000502:physiology*; D001324:Autoantigens / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000235:genetics* / Q000503:physiopathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics / Q000502:physiology*; D005260:Female; D005434:Flow Cytometry; D055785:Gene Knockdown Techniques; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D017239:Paclitaxel; D034741:RNA, Small Interfering / Q000235:genetics; D014410:Tumor Stem Cell Assay
chemical_list: D001324:Autoantigens; C500266:CIP2A protein, human; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D034741:RNA, Small Interfering; D017239:Paclitaxel
references.citation: Br J Cancer. 2011 Sep 27;105(7):989-95
references.pmid: 21897396
references.citation: Breast Cancer Res. 2012 Apr 26;14(2):R68
references.pmid: 22537901
references.citation: BMJ. 1991 Apr 6;302(6780):845-6
references.pmid: 2025711
references.citation: Bioorg Med Chem. 2012 Oct 15;20(20):6144-53
references.pmid: 22980218
references.citation: Exp Cell Res. 2000 Apr 10;256(1):42-9
references.pmid: 10739650
references.citation: Eur J Pharmacol. 2006 Dec 28;553(1-3):46-53
references.pmid: 17056031
references.citation: PLoS One. 2013 Oct 01;8(10):e75292
references.pmid: 24098375
references.citation: Ann Surg Oncol. 2011 Mar;18(3):857-65
references.pmid: 20842459
references.citation: Cell. 2007 Jul 13;130(1):51-62
references.pmid: 17632056
references.citation: Oncogene. 1998 Sep 17;17(11 Reviews):1395-413
references.pmid: 9779987
references.citation: Diagn Mol Pathol. 2012 Sep;21(3):143-9
references.pmid: 22847158
references.citation: Clin Cancer Res. 2012 Mar 15;18(6):1641-54
references.pmid: 22275507
references.citation: J Natl Cancer Inst. 2009 Jun 3;101(11):793-805
references.pmid: 19470954
references.citation: J Gastroenterol Hepatol. 2001 Jan;16(1):22-8
references.pmid: 11206311
references.citation: Pharm Res. 2015 Mar;32(3):769-78
references.pmid: 25823356
references.citation: Biochim Biophys Acta. 2007 Aug;1773(8):1150-60
references.pmid: 17229475
references.citation: PLoS One. 2011;6(5):e20159
references.pmid: 21655278
references.citation: FASEB J. 2008 Apr;22(4):954-65
references.pmid: 18039929
references.citation: Differentiation. 2010 Jul;80(1):68-77
references.pmid: 20447748
references.citation: Oncogene. 2002 Jul 25;21(32):5006-15
references.pmid: 12118381
references.citation: Curr Pharm Des. 2001 Nov;7(16):1581-94
references.pmid: 11562300
references.citation: J Gastrointest Surg. 2012 May;16(5):1037-47
references.pmid: 22328001
references.citation: Clin Cancer Res. 2009 Aug 15;15(16):5092-100
references.pmid: 19671842
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Cell Cycle. 2008 Mar 1;7(5):592-6
references.pmid: 18256542
references.citation: Front Biosci. 2008 Jan 01;13:440-52
references.pmid: 17981559
references.citation: Science. 2002 Dec 6;298(5600):1911-2
references.pmid: 12471242
references.citation: PLoS One. 2013;8(2):e55705
references.pmid: 23383345
references.citation: N Engl J Med. 1992 Jul 30;327(5):319-28
references.pmid: 1620171
references.citation: Oncogene. 2010 Nov 25;29(47):6257-66
references.pmid: 20729919
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3722-8
references.pmid: 18559589
references.citation: Nat Rev Cancer. 2005 Nov;5(11):876-85
references.pmid: 16239906
references.citation: Oncogene. 2012 Jan 19;31(3):390-401
references.pmid: 21706057
references.citation: Blood. 2011 Jun 16;117(24):6660-8
references.pmid: 21490338
references.citation: Breast. 2004 Jun;13(3):219-26
references.pmid: 15177425
references.citation: Med Oncol. 2013 Mar;30(1):406
references.pmid: 23275123
references.citation: Trends Pharmacol Sci. 1992 Apr;13(4):134-6
references.pmid: 1350385